Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
← catalyst calendarNCT05950945 · readout in 408 d
Sponsored by Daiichi Sankyo (industry) · 4568.T — their whole pipeline →. With AstraZeneca.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
250estimated
Sites
88
Countries
Australia, Belgium, Brazil +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-12-30 | actual | When the study began enrolling |
| Primary completion | 2027-10-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-10-01 | estimated | The whole study's end, after follow-up |
| First posted | 2023-07-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Breast Cancer
Intervention
- Drug: Trastuzumab Deruxtecan — also filed as T-DXd, DS-8201a (trastuzumab derextecan), Enhertu®
Primary outcome
what the primary-completion date above is the date OFTime From the Start of T-DXd to Initiation of Subsequent Anticancer Treatment (TTNT)
measured Until subsequent therapy or death, assessed up to 24 months
Publications
- PMID 41342740 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · 4568.T's whole pipeline · Catalyst calendar · Every registered study · What changed